Advertisement

Topics

Search Results for "Rituximab Patent"

11:05 EDT 24th April 2017 | BioPortfolio

Matching Channels

CD20 Antibodies

The chimeric anti-CD20 antibody rituximab (Rituxan & MabThera) from Biogen Idec and Genentech/Roche is one of the world’s commercially most successful antibodies (2007 sales of over US$ 5 bl...

Biosuperior Antibodies

After biosimilar versions of therapeutic proteins have become reality in Europe and in the US, now it’s the turn of therapeutic antibodies to be in the line of fire. Patents of the first wave of...

India

India, in the Asian subcontinent is the world’s fourth largest producer of pharmaceuticals, and is thought as one of the most promising biotech markets in the world. Several important steps ...

Tumor Necrosis Factor TNF Products

Tumor Necrosis Factor (TNF) and TNF receptor antagonists and agonists used to treat TNF-mediated inflammatory diseases such as rheumatoid arthritis or to treat cancer. TNF blockers are the commerc...

Matching News

Combating Rituximab-Induced Side Effects

I currently have a 77-year-old non-Hodgkin lymphoma patient that recently started bendamustine (Treanda)/rituximab combination therapy. After increasing the intravenous (IV) rituximab rate per protoco...

Rituximab Treatment in Neuromyelitis Optica Spectrum Disorders

Based on a meta-analysis and review of rituximab use in the treatment of neuromyelitis optica spectrum disorders, the authors reported that rituximab was efficacious in reducing relapse rate and disab...

Positive phase III results for Celltrion’s rituximab biosimilar

Phase III studies of a rituximab biosimilar from Celltrion have, according to the company, shown that the biosimilar is ‘equivalent’ to Roche’s MabThera/Rituxan (rituximab).

Rituximab biosimilar granted EU marketing authorisation

The European Commission has approved Truxima, a rituximab biosimilar, for all indications of reference rituximab in the European Union (EU). Truxima is a mAb that targets CD20, a protein found on t...

VIDEO: Harrold reviews study on rituximab to treat RA

WASHINGTON — At the American College of Rheumatology Annual Meeting, Leslie R. Harrold, MD, MPH, associate professor in the Department of Orthopedics and Physical Rehabilitation at the University of...

Rituximab in the Treatment of Inflammatory Myopathies

Get up-to-date on what there is to know about the use of rituximab therapy in the management of myositis. Rheumatology

B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patients

B cells are key players in the pathogenesis of rheumatoid arthritis (RA). Although successful in 50–60% of patients with RA, anti-B-cell therapy given as rituximab could be more efficient by identif...

JHL Forms $257 Million Partnership with Sanofi for Rituximab Biosimilar

JHL Biotech, a Taiwan-China biologics company, signed a $257 million partnership agreement that gives Sanofi  rights to market a JHL clinical-stage rituximab biosimilar, initially for China. Sano...

Matching PubMed Articles

Patent highlights June-July 2016.

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

Rituximab-induced lung disease.

Pulmonary toxicity is a rare complication of Rituximab therapy. Although Rituximab is relatively safe and can be administered in an outpatient setting, Rituximab-associated lung disease has been repor...

Rituximab: Uses in Dermatology.

Rituximab is an anti-CD20 monoclonal antibody with considerable potential in dermatology due to an increase in off-label indications. Chronic graft-versus-host disease and pemphigus vulgaris are two o...

Rituximab maintenance therapy for patients with diffuse large B-cell lymphoma: A meta-analysis.

The addition of rituximab to standard chemotherapy has significantly improved survival in patients with lymphoma. Recently, maintenance therapy with rituximab has been shown to prevent relapse and pro...

Rituximab-induced acute thrombocytopenia in a patient with chronic lymphocytic leukemia.

Rituximab is a chimeric anti-CD20 monoclonal antibody generally well tolerated. However, a severe but rare rituximab-related immune-toxic syndrome, associating fever, chills and thrombocytopenia can ...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement